Return to study ST002010 main page
MB Sample ID: SA188294
Local Sample ID: | QC_ov_2 |
Subject ID: | SU002091 |
Subject Type: | Cultured cells |
Subject Species: | Homo sapiens |
Taxonomy ID: | 9606 |
Select appropriate tab below to view additional metadata details:
Treatment:
Treatment ID: | TR002103 |
Treatment Summary: | The human OC cell line: CaOV3, was purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA) and the OVCAR-5 cell line obtained from Dr. Thomas Hamilton (Fox Chase Cancer Centre, Philadelphia, PA). Both cell lines were authenticated by short tandem repeat (STR) DNA profile in 2020. OVCAR-5 cells were grown in RPMI 1640 media (Sigma Aldrich, St. Louis, MO, USA). Recent reports indi-cate that OVAR-5 might originate from metastatic gastrointestinal cancer and were potentially wrong fully labelled as Ovarian cancer [25]. CaOV3 cells were grown in DMEM media (Sigma Aldrich, St. Louis, MO, USA). Both were cultured with the addi-tion of 10% foetal bovine serum (Bovogen Biologicals, East Keilor, VIC, AUS) supple-mented with 1% penicillin/streptomycin (Sigma Aldrich, St. Louis, MO, USA) and 1% L-glutamine (Sigma Aldrich, St. Louis, MO, USA). OVCAR-5 and CaOV3 cells were made resistant to CBP after treatment with 6-8 cycles of CBP (50μM, Hospira Austral-ia, Pty Ltd) [26,27]. Resistance to CBP was measured regularly and CBPR cell lines were seen to be at least two-fold more resistant to CBP than their parental partners through the following experiments. |
Treatment Compound: | Carboplatin |